ABIVAX press release
Abivax announces the holding of an ordinary and extraordinary ad hoc Meeting on November 9, 2022.
Abivax SA, a clinical-stage Phase 3 biotechnology company developing novel immune-modulating drugs to treat inflammatory diseases, viral diseases and cancer, today announces that an ad hoc Ordinary and Extraordinary General Meeting (l ‘ “General Meeting”) will be held on November 9, 2022 at 10:00 a.m. at the offices of Dechert (Paris) LLP, located at 32 rue de Monceau in Paris (75008).